Nov 4, 5:13 PM ET
On November 4, 2026, STERIS and its subsidiaries entered a new $1.6 billion revolving credit facility that replaces the existing credit agreement dated October 7, 2024, and a separate delayed draw term loan of up to $500 million. The term loan can be drawn only if STERIS completes its acquisition of Xodus Medical, Inc. For shareholders, the filing adds committed borrowing capacity tied to that acquisition, and the filing does not state the acquisition price or the amount that will be borrowed.
- Revolving credit facility of $1,600 million matures on November 4, 2031, with an incremental increase of up to $800 million available.
- Delayed draw term loan of up to $500 million can be used only after the Xodus Medical Acquisition is consummated and terminates if that deal is validly terminated or the outside date occurs.
- Term loan matures five years after the acquisition closing date; no principal is due in year one, then 1.25% quarterly in years two and three and 1.875% quarterly in years four and five.
- No borrowings were incurred to refinance the existing credit agreement at closing, and all term loan lenders are also lenders under the revolver.
Read the filing on SEC.gov ↗
Nov 4, 4:38 PM ET
STERIS plc reported total revenue of $1.6 billion for the second quarter of fiscal 2027, representing a 9% increase compared to the prior year period. Net income rose to $213.7 million, and the company updated its full-year adjusted EPS outlook to a range of $11.35 to $11.55.
- Total revenue for Q2 fiscal 2027 reached $1.6 billion, up 9% year-over-year.
- Diluted EPS as reported was $2.19, while adjusted diluted EPS increased to $2.94.
- Full-year fiscal 2027 adjusted EPS outlook was raised to a range of $11.35 to $11.55.
- The company approved a targeted restructuring plan anticipating total charges of approximately $45 million.
Read the filing on SEC.gov ↗
Oct 13, 4:29 PM ET
STERIS, through subsidiary STERIS Corporation, agreed on October 11, 2026 to acquire Xodus Medical, a Pennsylvania specialty surgical products business, for $2.1 billion in cash at closing, with up to $150 million more tied to calendar 2028 performance targets. The deal is expected to be financed mainly with debt, backed by a $2.0 billion bridge financing commitment, and is expected to close by December 31, 2026, subject to regulatory approvals.
- Cash price: $2.1 billion at closing, subject to customary adjustments, plus up to $150 million in earnout tied to calendar 2028 targets
- Financing: expected to be funded primarily with debt; $2.0 billion senior unsecured bridge facility from JPMorgan Chase Bank and Goldman Sachs Bank USA
- Timing: expected to close by December 31, 2026; either party may terminate if not closed by July 12, 2027, extendable to January 11, 2028
Read the filing on SEC.gov ↗
Aug 5, 4:33 PM ET
STERIS reported fiscal 2027 first-quarter revenue up 7% to $1.5 billion and diluted EPS of $2.04, up from $1.79, with adjusted EPS of $2.59 versus $2.34. It reiterated its full-year revenue and adjusted EPS guidance, but raised its capital expenditure outlook and lowered its free cash flow outlook, and it announced a consolidation of U.S. chemistries manufacturing that includes closing facilities in St. Louis, Missouri, and Plymouth, Minnesota.
- Q1 fiscal 2027 revenue rose 7% to $1.5 billion; Healthcare revenue grew 8% to $1.05 billion.
- Free cash flow fell to $279.6 million from $326.5 million; operating cash flow was $367.1 million versus $420.0 million.
- Expected pre-tax restructuring charges of $55 million to $70 million, with completion anticipated during fiscal 2030.
- Full-year free cash flow outlook cut to about $800 million from $850 million, while capital expenditures are now expected at about $450 million versus $375 million.
Read the filing on SEC.gov ↗
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
